胸腺肽α_1辅助治疗2型糖尿病合并侵袭性肺曲霉菌病的临床观察

Clinical Observation of Thymosin α_1 in Adjuvant Treatment of Type 2 Diabetes Mellitus Complicated with Invasive Pulmonary Aspergillosis

目的:探讨胸腺肽α_1辅助治疗2型糖尿病合并侵袭性肺曲霉菌病(IPA)患者的疗效及安全性。方法:50例2型糖尿病合并IPA患者随机分为观察组和对照组,对照组患者给予胰岛素降糖和伏立康唑抗曲霉菌治疗,疗程6~12周;观察组在此基础上给予胸腺肽α_11.6 mg·d^(-1)皮下注射,疗程4周。观察两组临床疗效及治疗前后CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平变化。结果:观察组治愈率明显高于对照组(P<0.05)。治疗后观察组CD3^+、CD4^+、CD4^+/CD8^+较前明显升高,CD8^+则较前明显降低(P<0.05);且与对照组比较差异有统计学意义(P<0.05)。结论:在IPA合并糖尿病的临床治疗上,除进行抢先抗真菌治疗外,提高免疫功能可明显提高临床疗效。

Objective： To investigate the clinical efficacy and safety of thymosin αl in the treatment of type 2 dia- betes mellitus （T2DM） with invasive pulmonary aspergillosis （IPA）. Methods ：Totally 50 cases of T2DM with IPA were randomly divided into the control group and the observation group. The routine treatment including insulin and voriconazole anti-fungal was carried out in the both groups for 6-12 weeks while the patients in the observation group were treated with thymosin cq, 1.6 mg · d -i, subcutaneous injection for 4 weeks additionally. The clinical efficacy and the level of CD3＋ , CD4 ＋ , CD8 ＋ , CD4＋/CD8 ＋ were detected before and after treatment in the two groups. Results： The recovery rate of the observation group was significantly higher than the control group （P 〈 0.05 ）. The values of CD3 ＋ , CD4 ＋ and CD4＋ / CD8＋ were significantly increased, while the values of CD8＋ was decreased significantly than before （P 〈 0.05 ）. The difference was statistically significant when compared with the control group （P 〈 0.05）. Conclusion： Increasing immune function besides antifungal treatment could significantly improve the clinical efficacy of T2DM patients with IPA.